Patents by Inventor Sabina Glozman
Sabina Glozman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230147602Abstract: This disclosure is directed to compounds and pharmaceutical compositions for treating and preventing viral diseases, as Covid-19. Among others, the invention relates to the use of ribonucleases and bioxoms, exosomes or combination thereof in the preparations and use of pharmaceutical formulations for the treatment of said disease. In addition, the invention relates to the use of immune cells and ribonucleases in the preparation and use of pharmaceutical formulations for the treatment of said disease.Type: ApplicationFiled: March 19, 2021Publication date: May 11, 2023Applicant: Orgenesis Inc.Inventors: JAMIE SULLEY, LUIS SQUIQUERA, THOMAS HODGE, SABINA GLOZMAN, Vered CAPLAN
-
Publication number: 20230072523Abstract: Process and system for acellular therapy in a human subject are provided. The process and system relate to an acellular therapy using therapeutic extracellular vehicles fused to biological material obtained from the subject, via transfusion by extracorporeal systems. The process for acellular therapy is in a subject in need of such therapy.Type: ApplicationFiled: January 28, 2021Publication date: March 9, 2023Applicant: Orgenesis Inc.Inventor: Sabina GLOZMAN
-
Publication number: 20210052506Abstract: Provided an artificial bioxome particle comprising a cell membrane component and designed to undergo fusion with a target cell, wherein said bioxome particle is engineered to carry a cargo comprising at least one predetermined active molecule; and wherein said cargo can be released into the target cell after the fusion of the bioxome particle with the target cell; and wherein the cell membrane component is derived from a selected cellular or extracellular source; methods of use of the particles; and processes for manufacturing thereof.Type: ApplicationFiled: April 4, 2019Publication date: February 25, 2021Applicant: ORGENESIS INC.Inventor: Sabina GLOZMAN
-
Publication number: 20190127702Abstract: The present method relates to methods of expanding or increasing stem cell production obtained from donor samples. The methods preferably including the steps of harvesting cells from minimally manipulated tissue using multiply harvesting cycles to increase the number of obtained stem cells.Type: ApplicationFiled: August 14, 2015Publication date: May 2, 2019Inventors: Irina KERKIS, Sabina GLOZMAN
-
Publication number: 20180187158Abstract: The present invention is directed to therapeutic multifunctional immature dental pulp stem cells (IDPSCs), and IDPSCs multi-lineage compositions. The invention is further directed to the use of IDPSCs and compositions to reduce the risk of and/or treat degenerative diseases or for other medicinal and aesthetic purposes.Type: ApplicationFiled: September 7, 2017Publication date: July 5, 2018Inventors: Irina Kerkis, Sabina Glozman
-
Patent number: 9790468Abstract: The present invention is directed to therapeutic multifunctional immature dental pulp stem cells (IDPSCs), and IDPSCs multi-lineage compositions. The invention is further directed to the use of IDPSCs and compositions to reduce the risk of and/or treat degenerative diseases or for other medicinal and aesthetic purposes.Type: GrantFiled: March 14, 2014Date of Patent: October 17, 2017Assignees: AVITA IINTERNATIONAL LTD., FUNDAÇCÃO BUTANTANInventors: Irina Kerkis, Sabina Glozman
-
Publication number: 20170119660Abstract: A pharmaceutical composition is provided for transmucosal administration of an active lipophilic compound through the oral mucosa comprising a lipophilic active compound, a polymeric matrix formed by two or more water-soluble polymers and a rapid dissolution agent. At least one of the water-soluble polymers is an amphiphilic polymer and at least one is either a hydrophilic polymer or an amphiphilic polymer with a hydrophobic-hydrophilic balance different from the first amphiphilic polymer. In addition, the polymeric matrix is not crosslinked and no covalent interaction occurs between the two or more polymers and between the polymers and the lipophilic active compound, which is interwoven with the aforesaid polymeric matrix.Type: ApplicationFiled: October 28, 2016Publication date: May 4, 2017Inventors: Galia TEMTSIN-KRAYZ, Sabina GLOZMAN, Pavel KAZHDAN
-
Patent number: 9579299Abstract: The present invention is directed to CNS pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a CNS active agent and preferably at least two vagal neuromodulators, one of which is a mechanoreceptor stimulator. The vagal neuromodulators are preferably in an amount sufficient to reduce a somnolence side-effect of the CNS active agent without changing its therapeutic efficacy/activity. The invention further encompasses a method of reducing CNS active agent side-effects. The method typically comprises oral administration of at least one CNS active agent to a patient at the conventionally accepted dose; and administration of at least two vagal neuromodulators to the patient so that at least one neuromodulator is administered or released from dosage form after the CNS active agent is administered and/or released.Type: GrantFiled: May 19, 2014Date of Patent: February 28, 2017Assignee: Targia PharmaceuticalsInventor: Sabina Glozman
-
Patent number: 9370481Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.Type: GrantFiled: April 19, 2011Date of Patent: June 21, 2016Assignee: Vecta, Ltd.Inventors: Aleksey Kostadinov, David Ayelet, Sabina Glozman, Tal Atarot
-
Patent number: 9278080Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.Type: GrantFiled: April 27, 2010Date of Patent: March 8, 2016Assignee: Vecta, Ltd.Inventors: Aleksey Kostadinov, Ayelet David, Sabina Glozman
-
Publication number: 20150050248Abstract: The present invention is directed to therapeutic multifunctional immature dental pulp stem cells (IDPSCs), and IDPSCs multi-lineage compositions. The invention is further directed to the use of IDPSCs and compositions to reduce the risk of and/or treat degenerative diseases or for other medicinal and aesthetic purposes.Type: ApplicationFiled: March 14, 2014Publication date: February 19, 2015Inventors: Irina Kerkis, Sabina Glozman
-
Publication number: 20140256709Abstract: The present invention is directed to CNS pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a CNS active agent and preferably at least two vagal neuromodulators, one of which is a mechanoreceptor stimulator. The vagal neuromodulators are preferably in an amount sufficient to reduce a somnolence side-effect of the CNS active agent without changing its therapeutic efficacy/activity. The invention further encompasses a method of reducing CNS active agent side-effects. The method typically comprises oral administration of at least one CNS active agent to a patient at the conventionally accepted dose; and administration of at least two vagal neuromodulators to the patient so that at least one neuromodulator is administered or released from dosage form after the CNS active agent is administered and/or released.Type: ApplicationFiled: May 19, 2014Publication date: September 11, 2014Applicant: TARGIA PHARMACEUTICALSInventor: Sabina Glozman
-
Patent number: 8729070Abstract: The present invention is directed to CNS pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a CNS active agent and preferably at least two vagal neuromodulators, one of which is a mechanoreceptor stimulator. The vagal neuromodulators are preferably in an amount sufficient to reduce a somnolence side-effect of the CNS active agent without changing its therapeutic efficacy/activity. The invention further encompasses a method of reducing CNS active agent side-effects. The method typically comprises oral administration of at least one CNS active agent to a patient at the conventionally accepted dose; and administration of at least two vagal neuromodulators to the patient so that at least one neuromodulator is administered or released from dosage form after the CNS active agent is administered and/or released.Type: GrantFiled: August 20, 2010Date of Patent: May 20, 2014Assignee: Targia PharmaceuticalsInventor: Sabina Glozman
-
Publication number: 20110250268Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.Type: ApplicationFiled: April 19, 2011Publication date: October 13, 2011Inventors: Aleksey Kostadinov, David Ayelet, Sabina Glozman, Tal Atarot
-
Patent number: 7981908Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.Type: GrantFiled: May 14, 2008Date of Patent: July 19, 2011Assignee: Vecta, Ltd.Inventors: Aleksey Kostadinov, David Ayelet, Sabina Glozman, Tal Atarot
-
Publication number: 20110054038Abstract: The present invention is directed to CNS pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a CNS active agent and preferably at least two vagal neuromodulators, one of which is a mechanoreceptor stimulator. The vagal neuromodulators are preferably in an amount sufficient to reduce a somnolence side-effect of the CNS active agent without changing its therapeutic efficacy/activity. The invention further encompasses a method of reducing CNS active agent side-effects. The method typically comprises oral administration of at least one CNS active agent to a patient at the conventionally accepted dose; and administration of at least two vagal neuromodulators to the patient so that at least one neuromodulator is administered or released from dosage form after the CNS active agent is administered and/or released.Type: ApplicationFiled: August 20, 2010Publication date: March 3, 2011Applicant: TARGIA PHARMACEUTICALSInventor: Sabina Glozman
-
Publication number: 20100247634Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.Type: ApplicationFiled: April 27, 2010Publication date: September 30, 2010Inventors: Aleksey Kostadinov, Ayelet David, Sabina Glozman
-
Patent number: 7803817Abstract: The present invention is related to oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and succinc acid as a parietal cell activator in the gastric lumen. The compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.Type: GrantFiled: July 27, 2005Date of Patent: September 28, 2010Assignee: Vecta, Ltd.Inventors: Aleksey Kostadinov, Ayelet David, Sabina Glozman
-
Publication number: 20080248109Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.Type: ApplicationFiled: May 14, 2008Publication date: October 9, 2008Applicant: VECTA, LTD.Inventors: Aleksey Kostadinov, David Ayelet, Sabina Glozman, Tal Atarot
-
Patent number: 7271146Abstract: The present invention relates to methods for treating pathological conditions associated with Helicobacter sp infections, specifically H. pylori infection. The present invention further relates to methods for treating pathologies characterized by excess gastric acid secretion. The methods of the present invention comprise oral administration of pentagastrin effective locally in the stomach in conjunction with a gastric proton pump inhibitor. It is disclosed herein for the first time that PG administered orally exerts a local effect in the stomach and may be used in combination with a PPI for treating pathological conditions characterized by excess gastric acid secretion and in pathological conditions associated with Helicobacter sp infections.Type: GrantFiled: October 14, 2003Date of Patent: September 18, 2007Assignee: Vecta Ltd.Inventor: Sabina Glozman